Saturday 10 October 2026 Export all IDXG data to Excel Powerpack

Interpace Biosciences, Inc.

IDXG

Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.

6.00 0.00 0.00%
Market cap
—
P/E
0.2×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
−6.95
Beneish M
2.07
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 5 5 6

+8 more TTM periods

ROE
221.93% 210.21% 243.97% (11.50%)
ROA
104.29% 98.74% 101.07% 25.58%
ROIC
12.67% 10.33% 12.85% 0.00%
Return on Tangible Assets
320.07% 323.25% 395.10% 70.57%
Average Days of Receivables
63.73 59.67 53.24 51.95
Free Cash Flow per Share
0.74 0.98 5.68 4.42
Free Cash Flow
4.10 4.45 5.03 3.91
Capital Expenditures
(0.35) (0.42) (0.81) (0.96)
Other line items
Cash ROIC
15.83% 17.31% 20.21% 347.73%
Accounts Receivable Turnover
5.34 4.93 5.46 6.32
Accounts Payable Turnover
9.34 10.70 11.05 10.23
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
43.32 21.64 24.58 32.34
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
5.22 6.67 5.62 0.00
Research and Development Expense of Revenue
1.64% 1.71% 1.66% 1.66%
Selling, General and Administrative Expense of Revenue
50.58% 51.51% 50.10% 49.46%
Share Based Compensation of Revenue
0.05% 0.07% 0.09% 0.25%
Operating CF/Net income
0.18 0.21 0.24 1.46
Depreciation/Fixed assets
0.57 0.69 0.62 0.55
Capex/Depreciation
(0.38) (0.47) (0.92) (1.13)
Revenue per Share
6.52 7.95 43.77 47.36
Operating CF per Share
0.80 1.07 6.59 5.51
Capex per Share
(0.06) (0.09) (0.91) (1.09)
Capex to Sales
0.01 0.01 0.02 0.02

Fold the line items

Columns are period end dates · fundamentals updated 28 Sep 2026